Next-Generation-Sequencing Approach to Neutropenic Sepsis
ConditionFebrile Neutropenia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBoris Böll
About this trial
The aim of this prospective, observational, non-interventional, multi-centre study of the diagnostic use of DISQVER in neutropenic patients with FN is to provide further evidence of the efficacy of an NGS-based approach for detecting bloodstream infection in neutropenic patients.
Eligibility criteria
Qualifiers
Age ≥18 years
Informed consent
Neutropenia defined as <500 ANC (Absolute neutrophil Count)/µl or <1000 WBC (White bloddcell Count)/µl if ANC is not available
Fever (with an onset < 24h) or Sepsis (with an onset <24h) Patients with a life-threatening - organ dysfunction caused by a dysregulated host response to a suspected or proven infection.
Disqualifiers
Age < 18 years
Refusal or inability to give consent Inability to give informed consent if no acceptable patient representative is available
Patients who had previously been included, but develop a new episode of fever during the same hospitalization, will not be included a second time
Death is deemed imminent and inevitable
Trial design
Treatments tested in this trial
- DISQVER
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov